Plain-English translation of NCT06943404 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called dexmedetomidine HCl (BXCL501) to see if it can help prevent or reduce acute stress symptoms and post-traumatic stress disorder (PTSD) in people who have just experienced a traumatic event. The medication comes as a thin film that dissolves under your tongue. Researchers believe this treatment may help calm the body's stress response in the critical hours and days after trauma.
After traumatic events like serious car accidents, many people experience overwhelming stress symptoms that can develop into long-term PTSD. This medication has shown promise in other medical conditions for reducing agitation and calming an overactive stress response, so researchers want to see if giving it early after trauma might help prevent these serious long-term effects.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive your first dose of either the medication or a placebo in the emergency department. You will then take a dose each night before bed for 14 days total. The study team will check in with you regularly through your smartphone and email to see how you're doing and track any symptoms. Your participation will last several weeks, with follow-up visits to assess your recovery and any stress-related symptoms.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States